Therapies based on targeting Epstein‐Barr virus lytic replication for EBV‐associated malignancies

In recent years, Epstein‐Barr virus (EBV) lytic infection has been shown to significantly contribute to carcinogenesis. Thus, therapies aimed at targeting the EBV lytic cycle have been developed as novel strategies for treatment of EBV‐associated malignancies. In this review, focusing on the viral l...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hongde, Hu, Jianmin, Luo, Xiangjian, Bode, Ann M., Dong, Zigang, Cao, Ya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029825/
https://www.ncbi.nlm.nih.gov/pubmed/29751367
http://dx.doi.org/10.1111/cas.13634
_version_ 1783337033118253056
author Li, Hongde
Hu, Jianmin
Luo, Xiangjian
Bode, Ann M.
Dong, Zigang
Cao, Ya
author_facet Li, Hongde
Hu, Jianmin
Luo, Xiangjian
Bode, Ann M.
Dong, Zigang
Cao, Ya
author_sort Li, Hongde
collection PubMed
description In recent years, Epstein‐Barr virus (EBV) lytic infection has been shown to significantly contribute to carcinogenesis. Thus, therapies aimed at targeting the EBV lytic cycle have been developed as novel strategies for treatment of EBV‐associated malignancies. In this review, focusing on the viral lytic proteins, we describe recent advances regarding the involvement of the EBV lytic cycle in carcinogenesis. Moreover, we further discuss 2 distinct EBV lytic cycle‐targeted therapeutic strategies against EBV‐induced malignancies. One of the strategies involves inhibition of the EBV lytic cycle by natural compounds known to have anti‐EBV properties; another is to intentionally induce EBV lytic replication in combination with nucleotide analogues. Recent advances in EBV lytic‐based strategies are beginning to show promise in the treatment and/or prevention of EBV‐related tumors.
format Online
Article
Text
id pubmed-6029825
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-60298252018-07-09 Therapies based on targeting Epstein‐Barr virus lytic replication for EBV‐associated malignancies Li, Hongde Hu, Jianmin Luo, Xiangjian Bode, Ann M. Dong, Zigang Cao, Ya Cancer Sci Review Articles In recent years, Epstein‐Barr virus (EBV) lytic infection has been shown to significantly contribute to carcinogenesis. Thus, therapies aimed at targeting the EBV lytic cycle have been developed as novel strategies for treatment of EBV‐associated malignancies. In this review, focusing on the viral lytic proteins, we describe recent advances regarding the involvement of the EBV lytic cycle in carcinogenesis. Moreover, we further discuss 2 distinct EBV lytic cycle‐targeted therapeutic strategies against EBV‐induced malignancies. One of the strategies involves inhibition of the EBV lytic cycle by natural compounds known to have anti‐EBV properties; another is to intentionally induce EBV lytic replication in combination with nucleotide analogues. Recent advances in EBV lytic‐based strategies are beginning to show promise in the treatment and/or prevention of EBV‐related tumors. John Wiley and Sons Inc. 2018-06-13 2018-07 /pmc/articles/PMC6029825/ /pubmed/29751367 http://dx.doi.org/10.1111/cas.13634 Text en © 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review Articles
Li, Hongde
Hu, Jianmin
Luo, Xiangjian
Bode, Ann M.
Dong, Zigang
Cao, Ya
Therapies based on targeting Epstein‐Barr virus lytic replication for EBV‐associated malignancies
title Therapies based on targeting Epstein‐Barr virus lytic replication for EBV‐associated malignancies
title_full Therapies based on targeting Epstein‐Barr virus lytic replication for EBV‐associated malignancies
title_fullStr Therapies based on targeting Epstein‐Barr virus lytic replication for EBV‐associated malignancies
title_full_unstemmed Therapies based on targeting Epstein‐Barr virus lytic replication for EBV‐associated malignancies
title_short Therapies based on targeting Epstein‐Barr virus lytic replication for EBV‐associated malignancies
title_sort therapies based on targeting epstein‐barr virus lytic replication for ebv‐associated malignancies
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029825/
https://www.ncbi.nlm.nih.gov/pubmed/29751367
http://dx.doi.org/10.1111/cas.13634
work_keys_str_mv AT lihongde therapiesbasedontargetingepsteinbarrviruslyticreplicationforebvassociatedmalignancies
AT hujianmin therapiesbasedontargetingepsteinbarrviruslyticreplicationforebvassociatedmalignancies
AT luoxiangjian therapiesbasedontargetingepsteinbarrviruslyticreplicationforebvassociatedmalignancies
AT bodeannm therapiesbasedontargetingepsteinbarrviruslyticreplicationforebvassociatedmalignancies
AT dongzigang therapiesbasedontargetingepsteinbarrviruslyticreplicationforebvassociatedmalignancies
AT caoya therapiesbasedontargetingepsteinbarrviruslyticreplicationforebvassociatedmalignancies

Ejemplares similares